Interestingly, tolvaptan, an antagonist of the vasopressin V2 receptor (V2R), has been found to moderately reduce ADPKD cysts [167] and suppress ccRCC tumor growth by decreasing cell proliferation and angiogenesis, as well as increasing apoptosis [168]. This evidence concerns the gene AVPR2 and autosomal dominant polycystic kidney disease.